TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02997605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucoCorticoid
Description: After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucoCorticoid
Description: After inclusion in the study, the first part is an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.~After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone.
Study: NCT03054181

Intervention type: BIOLOGICAL
Intervention: HyQvia
Study: NCT02870192

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy
Description: Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
Study: NCT00922116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
Study: NCT02720276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training after acute stroke
Description: Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
Study: NCT04328025

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer-delivered HIV self-testing, STI self-sampling and PrEP
Description: Peer delivery of combination HIV prevention interventions to transgender women.
Study: NCT02923583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M834

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-Sourced Orencia®

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: EU-Sourced Orencia®
Study: NCT03414190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text message
Description: The treatment group will receive the usual discharge treatment, instructions and information for acute coronary syndrome patients as well as the text-messaging intervention. The program will include a variety of topics such as standard follow-up care reminders as well as general self-management and healthy living habits texts. There will be four streams: one for patients who are non-smokers and are free of diabetes; one for current/recent smokers; one for diabetic patients; and one for smoker and diabetic patients. Texts will be sent out 4 times per week for 180 days. All participants in the same stream will receive the same texts in the same order. The usual care group will receive standard discharge treatment, instructions, and information for patients with acute coronary syndrome. They will also receive simple and short text messages related to the importance of trial participation.
Study: NCT02948647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care plus sugar-reduction education
Description: This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
Study: NCT01598610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTOUR® PLUS Investigational BG Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
Study: NCT03797898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Coach
Description: The Parent Coach intervention uses a health educator who provides anticipatory guidance, psychosocial screening/ referral, and developmental/behavioral surveillance, screening, and guidance at each well-visit. The Parent Coach uses a parent-focused, pre-visit questionnaire to customize the visit to the parents' needs. Every well-visit includes a brief, problem-focused encounter with a clinician for a physical exam and any concerns that require a clinician's attention. Finally, an automated text message service provides for periodic, age-specific messages to reinforce key health messages from Parent Coach-led well-visits.
Study: NCT02447445

Intervention type: PROCEDURE
Intervention: Grip strength assessment
Description: Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men \< 27 kg and women \<16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
Study: NCT00107562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Safer Sex Social Network Intervention
Study: NCT00354965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin/clavulanate potassium
Description: amoxicillin/clavulanate potassium
Study: NCT01639612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-451
Description: ALD-451 iv
Study: NCT04988204

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program
Description: The Diabetes Prevention Program is a 1 year validated program to prevent the development of type 2 diabetes. Participants with NAFLD will engage will work with a CDC certified DPP certified lifestyle coach and other participants in a group setting during the study focusing on lifestyle changes to achieve weight loss and improvement in NAFLD.
Study: NCT03286218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alprazolam
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study: NCT00539071

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-acting injectable risperidone
Description: Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long-acting injectable risperidone
Description: Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting injectable risperidone
Description: Study dose remains 50 mg for the length of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting injectable risperidone
Description: Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
Study: NCT04008225

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage

Intervention type: PROCEDURE
Intervention: Bronchoalveolar lavage
Study: NCT01861769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology-enhanced Teleconsultation
Description: Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Teleconsultation
Description: Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
Study: NCT02576262

Intervention type: PROCEDURE
Intervention: TCT，HPV，colposcopic inspection
Study: NCT00003494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02260817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-choline Injection
Description: 1. Choline C11 Injection for PET/CT Imaging Protocol:~   * 15 - millicuries (mCi) 11C-choline IV Injection~  * PET images skull base to mid thigh with 3 min per bed position~  * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol~  * Fusion of PET and CT images~2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:~   * No IV contrast~  * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs~  * Fusion of coronal and PET images
Study: NCT03519204

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLBELLA® XC with Lidocaine
Description: JUVÉDERM® VOLBELLA® XC with lidocaine injected into lips.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-treatment Control
Description: No-treatment was administered.
Study: NCT04419233

Intervention type: DRUG
Intervention: Nusinersen Sodium Injection
Description: Administered as specified in the treatment arm.
Study: NCT02597712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YF476
Description: gastrin receptor antagonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YF476 placebo
Description: placebo
Study: NCT01441635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol/Norethindrone acetate (E2/NETA)
Description: A continuous once-daily oral tablet containing estrogen and progestin; the low-dose strength contains estradiol 0.5 mg and norethindrone acetate 0.1 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 1.0 mg micronized estradiol tablets administered once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone 200 mg administered during the last 12 days of the 28-day menstrual cycle
Study: NCT04760262

Intervention type: DRUG
Intervention: Sevoflurane
Description: Sevoflurane %2-3 for general anesthesia maintenance, BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased

Intervention type: DRUG
Intervention: Propofol
Description: BIS values were arranged 40-60 until the end of operation, In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
Study: NCT04465955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM621
Description: NGM621 Dose 2

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham Comparator

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator
Description: Sham Comparator
Study: NCT04014231

Intervention type: PROCEDURE
Intervention: Diagnostic Imaging
Description: Undergo placement of single wave application

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT04154852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo to replace adalimumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Study: NCT00534495

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rilonacept
Description: 2.2 mg/kg subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rilonacept
Description: 2.2 mg/kg subcutaneously
Study: NCT01870947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise on stationary recumbent exercise cycle

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise on stationary recumbent exercise cycle
Study: NCT02511327

Intervention type: DRUG
Intervention: Infant pertussis vaccination
Description: Infants receive pertussis vaccines according to the national recommended schedule

Intervention type: DRUG
Intervention: Infant pertussis vaccination
Description: Infants receive pertussis vaccines according to the national recommended schedule

Intervention type: DRUG
Intervention: Infant pertussis vaccination
Description: Infants receive pertussis vaccines according to the national recommended schedule

Intervention type: DRUG
Intervention: Infant pertussis vaccination
Description: Infants receive pertussis vaccines according to the national recommended schedule
Study: NCT00987168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatine LP
Description: Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
Study: NCT01971814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
Study: NCT02376504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active workplace
Description: This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active workplace
Description: This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
Study: NCT03404986

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ureteroscopy
Description: The patients will be subjected to rigid ureteroscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: ureteroscopy
Description: The patients will be subjected to rigid ureteroscopy

Intervention type: RADIATION
Group type: OTHER
Intervention: Ultrasonography
Description: The patients will be subjected to Ultrasonography
Study: NCT02895269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative shared care
Description: Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
Study: NCT01870947

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)
Study: NCT02895269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Collaborative shared care
Description: Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
Study: NCT04474964

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose Craniospinal Irradiation plus Focal Radiotherapy
Description: The intervention arm of the study is to prospectively evaluate disease-related outcomes of low-dose CSI plus focal radiotherapy without concurrent chemotherapy followed by standard 6-cycles of adjuvant systemic chemotherapy in WNT-pathway medulloblastoma.
Study: NCT01129245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 400 mg PO daily intermittently based on hormone and ultrasound findings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex
Description: 400 mg PO daily intermittently based on hormone and ultrasound findings

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo identical to celecoxib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo identical to celecoxib
Study: NCT05186129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopid® 75 mg Tablet
Description: Single dose of Clopid® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plavix® 75mg Tablet
Description: Single dose of Plavix® 75 mg Tablet (Clopidogrel) was administered after a 10-hour overnight fast.